文献速递细菌感染、耐药与抗菌药物医院感染防控

头孢吡肟/恩美唑巴坦治疗革兰阴性假体周围关节感染:随机猪模型靶组织药代动力学研究

Cefepime/enmetazobactam for Gram-negative periprosthetic joint infections? A randomized porcine study on target tissue pharmacokinetics.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该临床前随机猪模型研究了头孢吡肟/恩美唑巴坦在假体周围关节感染相关组织中的分布及药效学达标情况。两种给药方式下所有组织隔室均达到预设药代动力学/药效学目标。

要点

  • 头孢吡肟/恩美唑巴坦在骨松质、皮下组织和滑液中组织分布良好
  • 间歇输注与持续输注均能达到预设PK/PD目标
  • 从药代动力学角度看,该组合可能用于革兰阴性假体周围关节感染

核心结论

  • 头孢吡肟/恩美唑巴坦在假体周围关节感染相关组织中分布稳健,无论给药方式均达到预设药代动力学/药效学目标。

研究设计与样本

  • 采用微透析动态采样骨松质、皮下组织和滑液中的间质液浓度,并采集血浆作为参照。

主要发现

  • 所有猪在两种给药方式下所有研究隔室均达到预设目标。
  • 头孢吡肟的平均T>MIC在所有目标、隔室、剂量间隔和给药方式下均≥92%。
  • 恩美唑巴坦的平均T>Ct在所有目标、隔室、剂量间隔和给药方式下均≥99%。

关键数值与推荐

  • 头孢吡肟的目标为60% T>MIC(MIC=8 mg/L)。
  • 恩美唑巴坦的目标为45% T>Ct(Ct=2 mg/L)。
  • 间歇短时输注方案:2 g/0.5 g over 2 h。
  • 持续输注方案:初始1 g/0.25 g over 15 min,随后2 g/0.5 g over 7 h 45 min。

临床怎么用

  • 从药代动力学角度支持头孢吡肟/恩美唑巴坦作为未来革兰阴性假体周围关节感染的潜在治疗选择。
  • 间歇短时输注和持续输注两种给药方式在组织分布和PK/PD达标方面均表现良好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Periprosthetic joint infections pose clinical and socioeconomic challenges. Gram-negative pathogens are associated with poorer outcomes compared with Gram-positive organisms. Rising antimicrobial resistance limits treatment options. The new combination of cefepime/enmetazobactam offers a promising carbapenem-sparing therapy. OBJECTIVES: To investigate the distribution and the time above the minimum inhibitory concentration for cefepime and the time above the threshold concentration for enmetazobactam during the first and third dosing intervals in tissues relevant to periprosthetic joint infection, following either intermittent short-term infusion or continuous infusion in a preclinical, randomized porcine model. MATERIALS AND METHODS: Sixteen pigs were randomized to receive cefepime/enmetazobactam either as a short-term infusion (2 g/0.5 g over 2 h) or continuous infusion (initial dosage of 1 g/0.25 g administered over 15 min followed by 2 g/0.5 g over 7 h and 45 min) in three dosing intervals of 8 h. Microdialysis was used to dynamically sample interstitial fluid concentrations of cefepime and enmetazobactam from cancellous bone, subcutaneous tissue and synovial fluid. Plasma samples were collected as reference. The following dosing interval targets were applied: for cefepime, 60% T > MIC of 8 mg/L and for enmetazobactam, 45% of T > Ct of 2 mg/L. RESULTS: All pigs reached the predetermined targets in all investigated compartments following both administration forms. For all targets, compartments, dosing intervals and administration forms, the mean T > MIC for cefepime was ≥92% and mean T > Ct for enmetazobactam was ≥99%. CONCLUSION: Cefepime/enmetazobactam demonstrated robust tissue distribution, reaching the applied pharmacokinetic/pharmacodynamic targets in all investigated tissue compartments, regardless of the mode of administration. From a pharmacokinetic view, cefepime/enmetazobactam may prove useful in future Gram-negative periprosthetic joint infection settings.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Nielsen MBD, Mikkelsen MKD, Rasmussen HC, et al. Cefepime/enmetazobactam for Gram-negative periprosthetic joint infections? A randomized porcine study on target tissue pharmacokinetics. J Antimicrob Chemother. 2026. PMID: 41549434. doi:10.1093/jac/dkaf487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。